Comparison of the Efficacy of Oxybutynin, Phenazopyridine, Celecoxib, and Placebo in the Treatment of Urinary Tract Symptoms after BCG Therapy in Patients with Bladder Tumors
Vol. 18 No. 04 (2021),
20 September 2021
Purpose: Intravesical BCG (Bacillus Calmette–Guérin) therapy is indicated as an effective treatment for patients with non-muscle-invasive bladder cancer, despite associate with the side effects. In this study, the incidence of BCG therapy adverse effects was compared among three groups of patients who received celecoxib, phenazopyridine, and oxybutynin with placebo.
Materials and Methods: The randomized controlled clinical trial was conducted on four groups using the parallel group method. A checklist is used for weekly assessment of urinary symptoms, systemic symptoms of BCG therapy, and adverse drug reactions.
Results: The study included 120 patients, 10 female and 110 male. The mean age 59.65 ± 6.2 years. The results of multivariate analysis show that there is a significant decrease in urinary frequency for patients who received phenazopyridine (95% CI: 0.09, 0.31, OR = 0.17, P <.001) and also celecoxib group (95% CI: 0.10, 0.43, OR = 0.21, P <.001) compared to those in placebo group. Patients in celecoxib group (95% CI: 0.02, 0.07 ,OR = 0.04, P <.001), phenazopyridine (95% CI : 0.07, 0.37,OR=0.16, P <.001) and oxybutynin (95% CI: 0.02, 0.12,OR = 0.05, P <.001) were less likely to have urgency than those in placebo. Moreover, significant decrease was found for dysuria in the three treatment groups in comparison with placebo group.
Conclusion: According to the results, celecoxib, phenazopyridine and oxybutynin can effectively decrease the side effects of BCG immunotherapy compared to placebo. Among these three treatments, the most effective and safest treatment option is celecoxib.
- non muscle invasive bladder cancer
- intravesical therapy
How to Cite
Garcia C, Jina H, Bergersen P, Chalasani V. Bladder Contracture e A Rare and Serious Side Effect of Intravesical Bacillus Calmette-Guérin Therapy. Urology Case Reports. 2016;4:22e4.
a MB, b JO, c RS, d AB, e CvdB, f GvA, et al. Side Effects of Bacillus Calmette-Gue´rin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG. EUROPEAN UROLOGY 6 5 2 0 1 4;65(1): 6 9 – 7 6.
SAINT F, IRANI J, PATARD JJ, SALOMON L, HOZNEK A, ZAMMATTIO S, et al. TOLERABILITY OF BACILLE CALMETTE-GUE´ RIN MAINTENANCE THERAPY FOR SUPERFICIAL BLADDER CANCER. UROLOGY. 2001;57( (5)):883–8.
Decaestecker K, Oosterlinck W. Managing the adverse events of intravesical bacillus Calmette–Guérin therapy. Research and Reports in Urology. 2015;7:163-57.
P M, Koya MA, Simon, Soloway MS. Complications of Intravesical Therapy for Urothelial Cancer of the Bladder. June 2006;175:2004-10.
Astram A, Khadijah A, Yuri P, Zulfan A, Mochtar CA, Danarto R, et al. Effective Dose and Adverse Effects of Maintenance Bacillus Calmette-Gue´Rin in Intermediate and High Risk Non-muscle Invasive Bladder Cancer: a Meta-analysis of Randomized Clinical Trial. Acta Medica Indonesiana - The Indonesian Journal of Internal Medicine. October 2014;46(4):298-307.
Gandhi NM, Morales A, Lamm DL. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer. BJU International. 2013;112:288–97.
Rocco Damiano MDS, Giuseppe Quarto, Giuseppe Di Lorenzo,, Sisto Perdonà IMP, Giuseppina Azzarito, Francesco Giugliano, Autorino aR. Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guérin-induced toxicity? B J U I N T E R N A T I O N A L. 2 0 0 9;104(5):6 3 – 6 3 9.
H M, Johnson, G K, Nepple, Peck V, Trinkaus K, et al. Randomized Controlled Trial of Oxybutynin Extended Release Versus Placebo for Urinary Symptoms During Intravesical Bacillus Calmette-Guérin Treatment. THE JOURNAL OF UROLOGY. April 2013;189:1268-74.
- Abstract Viewed: 0 times
- 5947/pdf Downloaded: 0 times